Exit

ISCT 2021 New Orleans Virtual CMLE Approved Program Evaluation

DAY 1 - LIVE SESSIONS

Question Title

* 1. Contact Information

Name

Company

Address 1

Address 2

City/Town

State/Province

Zip/Postal Code

Country

Email Address

Question Title

* 2. Professional Category

MT(ASCP)

HT/HTL(ASCP)

MLT(ASCP)

PBT(ASCP)

CT(ASCP)

Other, please specify

Question Title

* 3. Professional Practice Category

Technologist

Research (pre-clinical)

Manager/Supervisor

Translational Development

Medical Director

QA/Regulatory

Other, please specify

Question Title

* 4. Years of Experience

0-1 Year

2-5 Years

6-10 Years

11-20 Years

20+ Years

Session Evaluations
Please complete the evaluation for all of the sessions you attended/streamed.

Question Title

* 5. WEDNESDAY, MAY 26th, 2021 - LIVE Broadcast Sessions - CMLE Credits: 1.5 per session

The speakers’ level of expertise regarding content presented was:

	Excellent	Very Good	Good	Fair	Poor	N/A
Plenary Session - COVID-19: Understanding the Path Forward for Mesenchymal Stromal Cell Therapies	Plenary Session - COVID-19: Understanding the Path Forward for Mesenchymal Stromal Cell Therapies Excellent	Plenary Session - COVID-19: Understanding the Path Forward for Mesenchymal Stromal Cell Therapies Very Good	Plenary Session - COVID-19: Understanding the Path Forward for Mesenchymal Stromal Cell Therapies Good	Plenary Session - COVID-19: Understanding the Path Forward for Mesenchymal Stromal Cell Therapies Fair	Plenary Session - COVID-19: Understanding the Path Forward for Mesenchymal Stromal Cell Therapies Poor	Plenary Session - COVID-19: Understanding the Path Forward for Mesenchymal Stromal Cell Therapies N/A
MSC Session - MSC-Derived EVs: Cell Therapy without Cells	MSC Session - MSC-Derived EVs: Cell Therapy without Cells Excellent	MSC Session - MSC-Derived EVs: Cell Therapy without Cells Very Good	MSC Session - MSC-Derived EVs: Cell Therapy without Cells Good	MSC Session - MSC-Derived EVs: Cell Therapy without Cells Fair	MSC Session - MSC-Derived EVs: Cell Therapy without Cells Poor	MSC Session - MSC-Derived EVs: Cell Therapy without Cells N/A
Commercialization Session - Allogeneic Therapies - What Really is a Healthy Donor?	Commercialization Session - Allogeneic Therapies - What Really is a Healthy Donor? Excellent	Commercialization Session - Allogeneic Therapies - What Really is a Healthy Donor? Very Good	Commercialization Session - Allogeneic Therapies - What Really is a Healthy Donor? Good	Commercialization Session - Allogeneic Therapies - What Really is a Healthy Donor? Fair	Commercialization Session - Allogeneic Therapies - What Really is a Healthy Donor? Poor	Commercialization Session - Allogeneic Therapies - What Really is a Healthy Donor? N/A
MSC Session - Debating MSC Tissue Sources: Biological and Manufacturing Considerations	MSC Session - Debating MSC Tissue Sources: Biological and Manufacturing Considerations Excellent	MSC Session - Debating MSC Tissue Sources: Biological and Manufacturing Considerations Very Good	MSC Session - Debating MSC Tissue Sources: Biological and Manufacturing Considerations Good	MSC Session - Debating MSC Tissue Sources: Biological and Manufacturing Considerations Fair	MSC Session - Debating MSC Tissue Sources: Biological and Manufacturing Considerations Poor	MSC Session - Debating MSC Tissue Sources: Biological and Manufacturing Considerations N/A
Commercialization Session - Naming Cell & Gene Therapies – Harmonizing with INN Nomenclature and Regulatory Impact – A Joint ISCT – WHO Session	Commercialization Session - Naming Cell & Gene Therapies – Harmonizing with INN Nomenclature and Regulatory Impact – A Joint ISCT – WHO Session Excellent	Commercialization Session - Naming Cell & Gene Therapies – Harmonizing with INN Nomenclature and Regulatory Impact – A Joint ISCT – WHO Session Very Good	Commercialization Session - Naming Cell & Gene Therapies – Harmonizing with INN Nomenclature and Regulatory Impact – A Joint ISCT – WHO Session Good	Commercialization Session - Naming Cell & Gene Therapies – Harmonizing with INN Nomenclature and Regulatory Impact – A Joint ISCT – WHO Session Fair	Commercialization Session - Naming Cell & Gene Therapies – Harmonizing with INN Nomenclature and Regulatory Impact – A Joint ISCT – WHO Session Poor	Commercialization Session - Naming Cell & Gene Therapies – Harmonizing with INN Nomenclature and Regulatory Impact – A Joint ISCT – WHO Session N/A
Regulatory Session - The Path to a Biologics License Application (BLA)	Regulatory Session - The Path to a Biologics License Application (BLA) Excellent	Regulatory Session - The Path to a Biologics License Application (BLA) Very Good	Regulatory Session - The Path to a Biologics License Application (BLA) Good	Regulatory Session - The Path to a Biologics License Application (BLA) Fair	Regulatory Session - The Path to a Biologics License Application (BLA) Poor	Regulatory Session - The Path to a Biologics License Application (BLA) N/A
Presidential Plenary - Integrating Science, Regulatory Oversight, and Commercialization for the New Wave of Cell and Gene Therapies	Presidential Plenary - Integrating Science, Regulatory Oversight, and Commercialization for the New Wave of Cell and Gene Therapies Excellent	Presidential Plenary - Integrating Science, Regulatory Oversight, and Commercialization for the New Wave of Cell and Gene Therapies Very Good	Presidential Plenary - Integrating Science, Regulatory Oversight, and Commercialization for the New Wave of Cell and Gene Therapies Good	Presidential Plenary - Integrating Science, Regulatory Oversight, and Commercialization for the New Wave of Cell and Gene Therapies Fair	Presidential Plenary - Integrating Science, Regulatory Oversight, and Commercialization for the New Wave of Cell and Gene Therapies Poor	Presidential Plenary - Integrating Science, Regulatory Oversight, and Commercialization for the New Wave of Cell and Gene Therapies N/A
MSC Session - Understanding Regulatory Requirements for Potency Assays	MSC Session - Understanding Regulatory Requirements for Potency Assays Excellent	MSC Session - Understanding Regulatory Requirements for Potency Assays Very Good	MSC Session - Understanding Regulatory Requirements for Potency Assays Good	MSC Session - Understanding Regulatory Requirements for Potency Assays Fair	MSC Session - Understanding Regulatory Requirements for Potency Assays Poor	MSC Session - Understanding Regulatory Requirements for Potency Assays N/A
Commercialization Session - The Economic Impact on Healthcare and the Future of Advanced Cell & Gene Therapy	Commercialization Session - The Economic Impact on Healthcare and the Future of Advanced Cell & Gene Therapy Excellent	Commercialization Session - The Economic Impact on Healthcare and the Future of Advanced Cell & Gene Therapy Very Good	Commercialization Session - The Economic Impact on Healthcare and the Future of Advanced Cell & Gene Therapy Good	Commercialization Session - The Economic Impact on Healthcare and the Future of Advanced Cell & Gene Therapy Fair	Commercialization Session - The Economic Impact on Healthcare and the Future of Advanced Cell & Gene Therapy Poor	Commercialization Session - The Economic Impact on Healthcare and the Future of Advanced Cell & Gene Therapy N/A
MSC Session - Lessons & Recommendations for Clinical Trials of MSCs for Musculoskeletal Diseases in 2021	MSC Session - Lessons & Recommendations for Clinical Trials of MSCs for Musculoskeletal Diseases in 2021 Excellent	MSC Session - Lessons & Recommendations for Clinical Trials of MSCs for Musculoskeletal Diseases in 2021 Very Good	MSC Session - Lessons & Recommendations for Clinical Trials of MSCs for Musculoskeletal Diseases in 2021 Good	MSC Session - Lessons & Recommendations for Clinical Trials of MSCs for Musculoskeletal Diseases in 2021 Fair	MSC Session - Lessons & Recommendations for Clinical Trials of MSCs for Musculoskeletal Diseases in 2021 Poor	MSC Session - Lessons & Recommendations for Clinical Trials of MSCs for Musculoskeletal Diseases in 2021 N/A
Commercialization Session - Advancing the Translational Process through Automation & Equipment that Deliver Successful Scale Up/ Out in Cell Therapies	Commercialization Session - Advancing the Translational Process through Automation & Equipment that Deliver Successful Scale Up/ Out in Cell Therapies Excellent	Commercialization Session - Advancing the Translational Process through Automation & Equipment that Deliver Successful Scale Up/ Out in Cell Therapies Very Good	Commercialization Session - Advancing the Translational Process through Automation & Equipment that Deliver Successful Scale Up/ Out in Cell Therapies Good	Commercialization Session - Advancing the Translational Process through Automation & Equipment that Deliver Successful Scale Up/ Out in Cell Therapies Fair	Commercialization Session - Advancing the Translational Process through Automation & Equipment that Deliver Successful Scale Up/ Out in Cell Therapies Poor	Commercialization Session - Advancing the Translational Process through Automation & Equipment that Deliver Successful Scale Up/ Out in Cell Therapies N/A
Regulatory Session - Phishing for Cell Therapies – Therapeutic Deception	Regulatory Session - Phishing for Cell Therapies – Therapeutic Deception Excellent	Regulatory Session - Phishing for Cell Therapies – Therapeutic Deception Very Good	Regulatory Session - Phishing for Cell Therapies – Therapeutic Deception Good	Regulatory Session - Phishing for Cell Therapies – Therapeutic Deception Fair	Regulatory Session - Phishing for Cell Therapies – Therapeutic Deception Poor	Regulatory Session - Phishing for Cell Therapies – Therapeutic Deception N/A

Question Title

* 1. Contact Information

Question Title

* 2. Professional Category

Question Title

* 3. Professional Practice Category

Question Title

* 4. Years of Experience

Question Title

* 5. WEDNESDAY, MAY 26th, 2021 - LIVE Broadcast Sessions - CMLE Credits: 1.5 per sessionThe speakers’ level of expertise regarding content presented was:

Question Title

* 6. Total Credits on Wednesday:

* 5. WEDNESDAY, MAY 26th, 2021 - LIVE Broadcast Sessions - CMLE Credits: 1.5 per session

The speakers’ level of expertise regarding content presented was: